Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
South Korea
· Delayed Price · Currency is KRW 10,270
-40 (-0.39%)
At close: Apr 16, 2025, 3:30 PM KST
KRX:007570 Revenue
In the year 2024, Ilyang Pharmaceutical Co.,Ltd had annual revenue of 268.86B KRW with 0.82% growth. Ilyang Pharmaceutical Co.,Ltd had revenue of 8.52B in the quarter ending December 31, 2024, with 2,284.02% growth.
Revenue
268.86B
Revenue Growth
+0.82%
P/S Ratio
0.75
Revenue / Employee
422.07M
Employees
637
Market Cap
202.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 268.86B | 2.19B | 0.82% |
| Dec 31, 2023 | 266.67B | 18.90B | 7.63% |
| Dec 31, 2022 | 247.77B | 5.26B | 2.17% |
| Dec 31, 2021 | 242.51B | -100.82B | -29.36% |
| Dec 31, 2020 | 343.33B | 18.76B | 5.78% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 68.13B |
| Peptron | 3.15B |
| LigaChem Biosciences | 125.90B |